vs
Side-by-side financial comparison of Emergent BioSolutions Inc. (EBS) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $148.7M, roughly 1.8× Emergent BioSolutions Inc.). KILROY REALTY CORP runs the higher net margin — 6.3% vs -36.7%, a 43.0% gap on every dollar of revenue. On growth, KILROY REALTY CORP posted the faster year-over-year revenue change (-5.0% vs -23.6%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $73.8M). Over the past eight quarters, KILROY REALTY CORP's revenue compounded faster (-1.2% CAGR vs -29.6%).
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
EBS vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.7M | $272.2M |
| Net Profit | $-54.6M | $17.1M |
| Gross Margin | 42.9% | — |
| Operating Margin | -18.8% | — |
| Net Margin | -36.7% | 6.3% |
| Revenue YoY | -23.6% | -5.0% |
| Net Profit YoY | -74.4% | -73.7% |
| EPS (diluted) | $-0.95 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.7M | $272.2M | ||
| Q3 25 | $231.1M | $279.7M | ||
| Q2 25 | $140.9M | $289.9M | ||
| Q1 25 | $222.2M | $270.8M | ||
| Q4 24 | $194.7M | $286.4M | ||
| Q3 24 | $293.8M | $289.9M | ||
| Q2 24 | $254.7M | $280.7M | ||
| Q1 24 | $300.4M | $278.6M |
| Q4 25 | $-54.6M | $17.1M | ||
| Q3 25 | $51.2M | $162.3M | ||
| Q2 25 | $-12.0M | $79.6M | ||
| Q1 25 | $68.0M | $43.7M | ||
| Q4 24 | $-31.3M | $65.0M | ||
| Q3 24 | $114.8M | $57.7M | ||
| Q2 24 | $-283.1M | $54.5M | ||
| Q1 24 | $9.0M | $55.7M |
| Q4 25 | 42.9% | — | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 52.5% | — | ||
| Q1 25 | 60.2% | — | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | -18.8% | — | ||
| Q1 24 | 49.2% | — |
| Q4 25 | -18.8% | — | ||
| Q3 25 | 33.1% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 22.5% | — | ||
| Q4 24 | -4.9% | — | ||
| Q3 24 | 22.0% | — | ||
| Q2 24 | -79.9% | — | ||
| Q1 24 | 13.2% | — |
| Q4 25 | -36.7% | 6.3% | ||
| Q3 25 | 22.2% | 58.0% | ||
| Q2 25 | -8.5% | 27.4% | ||
| Q1 25 | 30.6% | 16.1% | ||
| Q4 24 | -16.1% | 22.7% | ||
| Q3 24 | 39.1% | 19.9% | ||
| Q2 24 | -111.2% | 19.4% | ||
| Q1 24 | 3.0% | 20.0% |
| Q4 25 | $-0.95 | $0.11 | ||
| Q3 25 | $0.91 | $1.31 | ||
| Q2 25 | $-0.22 | $0.57 | ||
| Q1 25 | $1.19 | $0.33 | ||
| Q4 24 | $-0.45 | $0.50 | ||
| Q3 24 | $2.06 | $0.44 | ||
| Q2 24 | $-5.38 | $0.41 | ||
| Q1 24 | $0.17 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $205.4M | $179.3M |
| Total DebtLower is stronger | $589.7M | — |
| Stockholders' EquityBook value | $522.6M | $5.4B |
| Total Assets | $1.3B | $10.9B |
| Debt / EquityLower = less leverage | 1.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $205.4M | $179.3M | ||
| Q3 25 | $245.5M | $372.4M | ||
| Q2 25 | $267.3M | $193.1M | ||
| Q1 25 | $149.1M | $146.7M | ||
| Q4 24 | $99.5M | $165.7M | ||
| Q3 24 | $149.9M | $625.4M | ||
| Q2 24 | $69.7M | $835.9M | ||
| Q1 24 | $78.5M | $855.0M |
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
| Q4 25 | $522.6M | $5.4B | ||
| Q3 25 | $582.5M | $5.5B | ||
| Q2 25 | $536.2M | $5.4B | ||
| Q1 25 | $552.7M | $5.4B | ||
| Q4 24 | $482.8M | $5.4B | ||
| Q3 24 | $508.4M | $5.4B | ||
| Q2 24 | $386.3M | $5.4B | ||
| Q1 24 | $663.9M | $5.4B |
| Q4 25 | $1.3B | $10.9B | ||
| Q3 25 | $1.5B | $11.0B | ||
| Q2 25 | $1.4B | $10.9B | ||
| Q1 25 | $1.4B | $10.9B | ||
| Q4 24 | $1.4B | $10.9B | ||
| Q3 24 | $1.5B | $11.4B | ||
| Q2 24 | $1.5B | $11.5B | ||
| Q1 24 | $1.8B | $11.6B |
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $77.7M | $566.3M |
| Free Cash FlowOCF − Capex | $73.8M | $450.3M |
| FCF MarginFCF / Revenue | 49.6% | 165.4% |
| Capex IntensityCapex / Revenue | 2.6% | 42.6% |
| Cash ConversionOCF / Net Profit | — | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | $156.8M | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.7M | $566.3M | ||
| Q3 25 | $-2.3M | $176.6M | ||
| Q2 25 | $106.4M | $143.7M | ||
| Q1 25 | $-11.2M | $136.9M | ||
| Q4 24 | $-79.9M | $541.1M | ||
| Q3 24 | $153.7M | $176.3M | ||
| Q2 24 | $47.5M | $88.7M | ||
| Q1 24 | $-62.6M | $167.9M |
| Q4 25 | $73.8M | $450.3M | ||
| Q3 25 | $-5.7M | $148.7M | ||
| Q2 25 | $103.5M | $118.4M | ||
| Q1 25 | $-14.8M | $115.6M | ||
| Q4 24 | $-81.6M | $440.8M | ||
| Q3 24 | $147.9M | $147.2M | ||
| Q2 24 | $42.9M | $69.5M | ||
| Q1 24 | $-73.4M | $151.9M |
| Q4 25 | 49.6% | 165.4% | ||
| Q3 25 | -2.5% | 53.1% | ||
| Q2 25 | 73.5% | 40.9% | ||
| Q1 25 | -6.7% | 42.7% | ||
| Q4 24 | -41.9% | 153.9% | ||
| Q3 24 | 50.3% | 50.8% | ||
| Q2 24 | 16.8% | 24.7% | ||
| Q1 24 | -24.4% | 54.5% |
| Q4 25 | 2.6% | 42.6% | ||
| Q3 25 | 1.5% | 10.0% | ||
| Q2 25 | 2.1% | 8.7% | ||
| Q1 25 | 1.6% | 7.9% | ||
| Q4 24 | 0.9% | 35.0% | ||
| Q3 24 | 2.0% | 10.1% | ||
| Q2 24 | 1.8% | 6.8% | ||
| Q1 24 | 3.6% | 5.7% |
| Q4 25 | — | 33.10× | ||
| Q3 25 | -0.04× | 1.09× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | -0.16× | 3.13× | ||
| Q4 24 | — | 8.32× | ||
| Q3 24 | 1.34× | 3.06× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | -6.96× | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
KRC
Segment breakdown not available.
